This is probably the most impressive Alzheimers trial with dietary suppplements that I have ever seen:
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
January 2023
A cocktail of 4 dietary supplements showed a 29% improvement in cognitive function when given to Alzheimer's patients over a period of almost 3 months (verses 14% in the placebo group).
This was a phase 2 randomized controlled trial with 69 people. There were 47 people randomized to the intervention group, and 22 to controls.
The most impressive thing is that there were positive changes in cortical brain thickness on imaging, and the treatment group maintained their hippocampal volumes, which declined in the placebo group. This phase 2 study will be expanded in an upcoming phase 3 randomized trial.
They call this supplement cocktail CMA, for combined metabolic activators. One dose included 12.35g L-serine, 1g nicotinamide riboside, 2.55g N-acetyl-L-cysteine, and 3.73g L-carnitine tartrate. AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84.
Quoted:
“We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment.”
“Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.”
Paper · Transl Neurodegener · 2023Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial.Conclusion: Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis. Trial registration ClinicalTrials.gov NCT04044131 Registered 17 July 2019, https://clinicaltrials.gov/ct2/show/NCT04044131.link.springer.com#alzheimersHD #dementiaHD #cmaHD #serineHD #nrHD #nacHD #carnitineHD



